It inhibits metastatic castrate resistance to prostate cancer (mCRPC) by selectively inhibiting CYP17A1 (a member of the city-P450 superfamily of enzymes) in an irreversible manner [44]. This evidence concerns the gene CYP2B6 and prostate cancer.